Business Description
MIRA Pharmaceuticals Inc. is a Miami-based drug development company founded in 2020, focused on building two early-stage treatments for brain and mental health conditions. Its lead candidate, Ketamir-2, is an oral form of ketamine designed to work quickly against severe depression, suicidal thoughts, and post-traumatic stress disorder, with exclusive rights covering the United States, Canada, and Mexico. The company is also developing MIRA-55, an oral cannabis-based medicine aimed at reducing anxiety and slowing cognitive decline in adults showing early signs of dementia.
